{"name":"ADvantage Therapeutics","slug":"advantage-therapeutics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"AD04","genericName":"AD04","slug":"ad04","indication":"Type 2 diabetes","status":"phase_2"}]}],"pipeline":[{"name":"AD04","genericName":"AD04","slug":"ad04","phase":"phase_2","mechanism":"AD04 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxQY3UwY1lQVlBJUUgzR0QtY3JMZ0V2aEl1a2VNUUdGdzN6WC12djlZbjI0SzRSQnZvN09kSDNMN3ZiUXlPWGtLWUhkWTg1TWFCb0VkWTd3bV9Ob0NxTkFRYVM0U2NWc2VwZlgwZXJlWk44M2lwUTRsZTk1ODc2QVFKbUl3V2o4ZTdDdDR1dUQ5RHRidWU1ZTVJNzdVcUZZZ0FrWHJKM1M4VGdFZ1F5UUE?oc=5","date":"2026-02-09","type":"pipeline","source":"Information Technology and Innovation Foundation (ITIF)","summary":"Tracking R&D Leadership: US Advantage Narrowing as China Gains Ground | Reports & Briefings | Feb 9, 2026 - Information Technology and Innovation Foundation (ITIF)","headline":"Tracking R&D Leadership: US Advantage Narrowing as China Gains Ground | Reports & Briefings | Feb 9, 2026 - Information ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxPQ2h6VThSYkZtb1lXRHhpQzIyaGFnNG1RajloRkxfNTFINmpuSTVEdXdreU5jMVdCT1BVanJ3bzRtZTZvQ19aXzl3cHNPckhqZXhQbWFucXRZRkRWb2hoang4eUh0OTdPT3Z2RU1QdFl0dlFEX0NjOGEzZ2lvUWY3NFAyRWgxSFAzSFBfQTBKc2pPUHlOODJwZ2htTlQxenhmZ3lva2lpR2pENDliTUNJc0RGMHFzLTdmT213WXNUdHVZa3UxZmw0WFE3RkV3X1RBQ0ZWT1pZZjlwR0RxNmJBSzNNYw?oc=5","date":"2026-01-30","type":"pipeline","source":"Reuters","summary":"Regeneron bets added cholesterol benefit will help its obesity drug stand out - Reuters","headline":"Regeneron bets added cholesterol benefit will help its obesity drug stand out","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-08","type":"trial","source":"Business Wire","summary":"ENYO Pharma Announces Completion and Topline Data From Phase 2 Alpestria-1 Clinical Study in Alport Syndrome Demonstrating Vonafexor Reverses Kidney Function Decline and Has Sustained Therapeutic Bene","headline":"ENYO Pharma Announces Completion and Topline Data From Phase 2 Alpestria-1 Clinical Study in Alport Syndrome Demonstrati","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxNbTdFNmNwaVIybXFNcmR2TlNEX0pqZUh4S2t5NTRCbUNHb0VmRTRuY3E4ZnFhcHhZYlZBT3JtenNuWkNIMUp6ZmdXUnpBYjZYYVdieGUyb0tZaE1NcUhYNmdoUzFhVUwxeFp3SDhDNTZCN2JfQjFYUTUzdW4ybGMzLXQ3bHhhMU9CTWNobzJrWEFITlRta2RyX0t6ZlZoMGgx?oc=5","date":"2025-11-05","type":"pipeline","source":"Yahoo Finance","summary":"Rhythm Pharmaceuticals Announces Public Reimbursement for IMCIVREE® (setmelanotide) in Canada in Five Provinces and Under the Federal Non-Insured Health Benefits Program - Yahoo Finance","headline":"Rhythm Pharmaceuticals Announces Public Reimbursement for IMCIVREE® (setmelanotide) in Canada in Five Provinces and Unde","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxNMzBPQW81SVZWVTg5cEwtRlJXdFVMeEVtX2poMDZqWTItcnRvYlUyblNSR3NpZ1ZLUFhhSW42WVM5VXdvZUFUQlpZRld1OXA5THhydU9ZcW5TWEZrOU1OZFRPWHVVUjhMYTdCd2NvWkNwLXBrMTVaaFV6eFRMektNbktMNENWT3BOMWlET0t1ZW1jSDg?oc=5","date":"2025-10-30","type":"pipeline","source":"McKinsey & Company","summary":"Agentic AI advantage for pharma - McKinsey & Company","headline":"Agentic AI advantage for pharma - McKinsey & Company","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5DZkxLNTI5SlF6TDBHUlBnYVVfR0g4QjdIQ1B0RkhaRHM3ajlKSjlFREh1VVU1Y3FCMFNKSms1MmVIWGJOTUYtenNudlFjcGoyRGlDaXozZVdmamplOVZN?oc=5","date":"2025-10-06","type":"pipeline","source":"Nature","summary":"Lifetime benefits of comprehensive medical therapy in heart failure with mildly reduced or preserved ejection fraction - Nature","headline":"Lifetime benefits of comprehensive medical therapy in heart failure with mildly reduced or preserved ejection fraction","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-07-31","type":"regulatory","source":"Express Pharma","summary":"Early Alzheimer's patients continue to benefit from 4 yrs of LEQEMBI(R) (lecanemab-irmb) Therapy, new clinical data presented at AAIC - Express Pharma","headline":"Early Alzheimer's patients continue to benefit from 4 yrs of LEQEMBI(R) (lecanemab-irmb) Therapy, new clinical data pres","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxQUUprMEpDS1NNWTRwQUlvVFBDYUJtY01YY2dJb3VCM3ZHNklWMlpzZGhIa2N2V0J2ekxKMXRHOUdTUl8tOHdJdmdDLURvdVZ5WHBvWVNJcjBoejdFak5ZMUJ1QzRVWm5weHJ3LUp6VWYybC1QT3NvSFhfUEVDak1valJ2UHdpdXl0dDM4ZGRuZkVycGlp?oc=5","date":"2025-07-14","type":"pipeline","source":"fiercepharma.com","summary":"The advantages of lab-based RWD for precise HCP identification - fiercepharma.com","headline":"The advantages of lab-based RWD for precise HCP identification","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNMTl4cnN0RmhVRjZvMUE2UUpDTHEyV1hmUTF5ZHk0Qzg0T1kxV3MzSy1aMDZJQnZxTTRBY3poY1c4eThBTjl0anlRSVNRaXlkaTgwQVJ6YXc3ZDR3THVwb1ZYYUROQzhqUDZJTTdsU0lNZ0huREtBNV9YVlJTaW55LXFCZ0kyUWdXS3pwaWswY1RqS3Z5dkp5aThNcFZPMTQzcGp0S2UzLVdXUFBRbmdkQWl3V3RTT0JTWnNlem9ZUQ?oc=5","date":"2025-06-20","type":"trial","source":"Pharmaceutical Executive","summary":"China’s Trial Advantage: Tracking Nation’s Growth in Pharma Innovation and Global Investment - Pharmaceutical Executive","headline":"China’s Trial Advantage: Tracking Nation’s Growth in Pharma Innovation and Global Investment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxPM0tiRWlneEZOVnU4SUFTUlBGeHlDSjFXZEEybVZUYU0tWE9oMXZaNjRiM3J1LWs0TF9kSF8zcFo1c3Q2SjNaRWI0b25CYTlYX0dIalh5emlZbXFRRW5QV0otM1RyQ1JWLURCYVhxWTFaTm1naC1lcVhxeXBqblhhSUd2TnVYQ3ZuemNpb0Z1cWxmX2xDV055ag?oc=5","date":"2025-06-03","type":"pipeline","source":"Contract Pharma","summary":"Late-Stage Cell Therapy: Key Challenges and the CDMO Advantage - Contract Pharma","headline":"Late-Stage Cell Therapy: Key Challenges and the CDMO Advantage","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNMmNuQ2FpbU1yWFFBSjJvSzlFVGNIMFpfNXVRQXU2clhCOEluSm4ycnFrTjRGd2IxQlcwRkdXYkdSNk5KMTJTNjd0eVhTb1NxazRPZEYydmhjeUZCM0Y4UURzTkhFUFF2N253eGt0MzNDNUEzOHFpT0VUbWZVTDVQNHQxMEFiSnE4S2FJ?oc=5","date":"2025-05-28","type":"pipeline","source":"World Intellectual Property Organization (WIPO)","summary":"PAILL: Driving Innovation, Quality, and Empowerment in Salvadoran Pharmaceuticals - World Intellectual Property Organization (WIPO)","headline":"PAILL: Driving Innovation, Quality, and Empowerment in Salvadoran Pharmaceuticals - World Intellectual Property Organiza","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxPcmFxNVJzMDNlT1E3R2xHT0lCamFTenNKTHJBZUxFdk9JMGVsQkhadThqdlFfWnlPbjIwdW42cTFCbnJ4cmFBQkNzNHdpRWs5T2pCYlplckdfR2pRUzljRjV6ZDF1RUhfeHo5ZTdXdUhkRGx3NmE4LUcxS3RYUlVoZzgyeEg2X2NCeXUwLVhzekJ1OTJhcFZ5VThB?oc=5","date":"2025-05-08","type":"pipeline","source":"National Association of Manufacturers - NAM","summary":"NAM Details Impact of Potential Pharma, Chips Tariffs for Administration - National Association of Manufacturers - NAM","headline":"NAM Details Impact of Potential Pharma, Chips Tariffs for Administration - National Association of Manufacturers","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}